– USA, CA – Alto Neuroscience, Inc. (NYSE: ANRO) today announced the appointment of Dr. Maha Radhakrishnan (M.D.) to its Board of Directors.
About Dr. Maha Radhakrishnan
Dr. Maha Radhakrishnan is an accomplished industry executive with decades of experience advancing large strategic portfolios across different therapeutic areas through product development and commercialization and overseeing the global medical strategy and operations within major biotechnology and pharmaceutical companies.
Dr. Maha Radhakrishnan recently served as group SVP and CMO of Biogen, responsible for the worldwide medical function, until March 2024. Previously,
Dr. Maha Radhakrishnan was SVP and global head of medical, and primary care business unit at Sanofi, a global biopharmaceutical company focused on human health. At Sanofi, she led the function of providing the medical strategy for diabetes and cardiovascular products and programs in development. Prior, she held several leadership roles at Bioverativ Inc., Bristol Myers Squibb, United Health Group, and Cephalon. Dr. Radhakrishnan received her M.D. in internal medicine with honors from the People’s Friendship University in Moscow, Russia in 1995, as well as a master’s degree in Russian language.
“The emergence of precision psychiatry is critically important given the urgent need to address the disparities in individual responses across treatments in mental healthcare,” said Dr. Maha Radhakrishnan. “I am honored to join Alto’s board at such an exciting time in the company’s journey and I am encouraged by the data that has been exhibited across the company’s programs to date. I believe successful stratification of patients can unlock the ability to redefine psychiatric care in a truly meaningful way and Alto’s Precision Psychiatry Platform has the potential to pioneer this transformation.”
About Alto Neuroscience
Alto Neuroscience is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment options. Alto’s Precision Psychiatry Platform™ measures brain biomarkers by analyzing EEG activity, neurocognitive assessments, wearable data, and other factors to better identify which patients are more likely to respond to Alto product candidates. Alto’s clinical-stage pipeline includes novel drug candidates for depression, PTSD, schizophrenia, and other mental health conditions.
For more information: www.altoneuroscience.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.